Objective: We aimed to investigate the effects of warfarin and new-generation oral anticoagulants on the prognosis of patients diagnosed with coronavirus disease 2019 (COVID-19). Materials and methods: Patients diagnosed with COVID-19 were divided into two groups depending on whether they were using warfarin or a new-generation oral anticoagulant. The types of chronic diseases, drugs used, haematological and biochemical parameters and prognoses in each group were statistically analysed.
Results: Twenty-three patients (37.1%) using warfarin and 39 (62.9%) patients using new-generation oral anticoagulants were included in the study. There was no significant difference between the two groups in terms of demographic characteristics and laboratory data. The mortality rates for the warfarin and new-generation anticoagulant groups were similar (39.1% vs. 43.6%, respectively; p=0.731).
Conclusion: There was no difference in the effects of warfarin and new-generation oral anticoagulants on mortality among the patients with COVID-19.